Cat. #161729
Anti-AnxA6 [9E1]
Cat. #: 161729
Sub-type: Primary antibody
Availability: 3-4 weeks
Target: AnxA6 antigen
Class: Monoclonal
Application: WB, IP, IHC, ELISA
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Prof Martin Clynes
Institute: Dublin City University
Primary Citation: O'Sullivan D, et al. 2017. Br J Cancer. 1326-1335. PMID: 28881357
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-AnxA6 [9E1]
- Cancer: Breast cancer;Lung cancer;Pancreatic cancer
- Research fields: Cancer
- Clone: 9.00E+01
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: No
- Reactivity: Human
- Host: Mouse
- Disease: Cancer
- Application: WB, IP, IHC, ELISA
- Description: A highly invasive clonal variant of the MDA-MB-435S cell line was used to generate MAb 9E1, which was screened for anti-invasive activity against aggressive cancer cells in vitro.
- Isotype: IgG1
Target Details
- Target: AnxA6 antigen
- Target background: Annexin VI belongs to a family of calcium-dependent membrane and phospholipid binding proteins. Although their functions are still not clearly defined, several members of the annexin family have been implicated in membrane-related events along exocytotic and endocytotic pathways. AnxA6 is suggested to be functionally involved in the invasive phenotype of PDAC and lung squamous cancer in vitro.
Applications
- Application: WB, IP, IHC, ELISA
Handling
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
References
- O'Sullivan D, et al. 2017. Br J Cancer. 1326-1335. PMID: 28881357